Search results
Results from the WOW.Com Content Network
Signal Transduction and Targeted Therapy is a multidisciplinary peer-reviewed open access scientific journal covering biomedical research with a particular focus on signal transduction and its application to the drug development process. It was established in 2016 and is published by Nature Research.
The Division of Signal Transduction Therapy or DSTT is an organization managed by the University of Dundee, [1] the Medical Research Council, and the pharmaceutical companies AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Serono, Janssen Pharmaceutica, and Pfizer.
The Linker for activation of T cells, also known as linker of activated T cells or LAT, is a protein involved in the T-cell antigen receptor signal transduction pathway which in humans is encoded by the LAT gene. [5] Alternative splicing results in multiple transcript variants encoding different isoforms. [6]
Tyrosine kinases are enzymes responsible for the activation of many proteins by signal transduction cascades. The proteins are activated by adding a phosphate group to the protein (phosphorylation), a step that TKIs inhibit. TKIs are typically used as anticancer drugs.
The lack of an efficient way for gene transduction is the major limitation of CAR-NK therapy. Although retroviral vectors exhibit up to 70% efficiency with the presence of membrane-bound cytokines, it would bring problems such as insertional mutagenesis and reduced NK viability. While lentivirus transduction generally causes lower genotoxicity ...
Molecular Cancer publishes research articles, reviews, and commentaries related to cancer biology, molecular oncology, cancer genetics, epigenetics, signal transduction, and targeted therapy. [ 2 ] Abstracting and indexing
Cobimetinib or XL518, approved by US FDA in Nov 2015 for use in combination with vemurafenib (Zelboraf(R)), for treatment of advanced melanoma with a BRAF V600E or V600K mutation. Selumetinib , had a phase 2 clinical trial for non-small cell lung cancer (NSCLC) which demonstrated an improvement in PFS, [ 5 ] and is now in phase III development ...
Weichselbaum's research interests range from innovative multidisciplinary clinical programs in head and neck cancer treatments, to laboratory studies of repair signal transduction and DNA recombination, ionizing radiation, gene-targeted radiotherapy, chemoprevention, gene expression profiling in cancer, and angiogenic therapy. Much of this work ...